Drug Development

Clinical Trials Preclinical Studies Phase 3 Trials Monoclonal Antibodies Therapeutics Cancer Therapies FDA Approval Regulatory Affairs Regulatory Approval Nektar Therapeutics

4 ARTICLES

3w ago

Sandoz Signs Exclusive Deal to Commercialize Up to 10 Henlius Biosimilars

The agreement gives Sandoz global ex-China registration and sales rights under a $322 million milestone framework that could accelerate Henlius’ early-stage antibody programs.

3 ARTICLES

4w ago

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

10 ARTICLES

3mo ago

Mexico Seeks Role as Latin America Clinical-Trial Hub With New Funding and AI

6 ARTICLES

3mo ago

Immunovant Shares Surge on Strong Rheumatoid Arthritis Data for IMVT-1402

7 ARTICLES

4mo ago

UNAM Scientists Turn Scorpion Venom and Habanero Chili Into Experimental Antibiotics

7 ARTICLES

4mo ago

Oral GLP-1 Weight-Loss Pills Curb Hedonic Eating by Hitting Deep-Brain Circuit in Mice

4 ARTICLES

4mo ago

Five-Target ‘Trojan Horse’ Drug Outperforms Leading Incretins in Obese Diabetic Mice

4 ARTICLES

4mo ago

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

4 ARTICLES

4mo ago

FDA Issues Second Rejection of Replimune’s RP1 Melanoma Therapy

4 ARTICLES

7mo ago

Cholera-Derived Toxin Slows Colorectal Tumors in Mice, Rewiring Local Immunity

4 ARTICLES

10mo ago

BioNTech Raises 2025 Sales Outlook After $1.5 Billion BMS Payment

8 ARTICLES

10mo ago

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

3 ARTICLES

11mo ago

Biomea Fusion Prices Equity Offering With Warrants to Raise About $25 Million

3 ARTICLES

11mo ago

FDA Signals Openness to Accelerated Path for Lexeo’s Friedreich’s Ataxia Cardiac Gene Therapy

3 ARTICLES

11mo ago

AI Pinpoints Target of New IBD Antibiotic Enterololin, Speeding Development

Drug Development

Sandoz Signs Exclusive Deal to Commercialize Up to 10 Henlius Biosimilars

LMU Team Creates Reproducible 3D Human Brain Spheroid That Models Alzheimer’s

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

Oral Antiviral Candidate Stops Measles-Like Virus Transmission in Ferret Study

McMaster Scientists Discover Manikomycin, a New Antibiotic Candidate

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Mexico Seeks Role as Latin America Clinical-Trial Hub With New Funding and AI

Immunovant Shares Surge on Strong Rheumatoid Arthritis Data for IMVT-1402

UNAM Scientists Turn Scorpion Venom and Habanero Chili Into Experimental Antibiotics

Never miss stories about

Drug Development

Oral GLP-1 Weight-Loss Pills Curb Hedonic Eating by Hitting Deep-Brain Circuit in Mice

Five-Target ‘Trojan Horse’ Drug Outperforms Leading Incretins in Obese Diabetic Mice

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

FDA Issues Second Rejection of Replimune’s RP1 Melanoma Therapy

Cholera-Derived Toxin Slows Colorectal Tumors in Mice, Rewiring Local Immunity

BioNTech Raises 2025 Sales Outlook After $1.5 Billion BMS Payment

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Biomea Fusion Prices Equity Offering With Warrants to Raise About $25 Million

FDA Signals Openness to Accelerated Path for Lexeo’s Friedreich’s Ataxia Cardiac Gene Therapy

AI Pinpoints Target of New IBD Antibiotic Enterololin, Speeding Development

Never miss stories about

Drug Development